Ahearn Matthew Fraser sold $374K of SI

Ahearn Matthew Fraser (Chief Operating Officer) sold 20,000 shares of SHOULDER INNOVATIONS, INC. (SI) at an average of $18.71 ($18.20–$19.26, $0.37M total) across 3 trades over 2026-06-12 to 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ahearn Matthew Fraser
Published Jun 16, 2026, 8:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SI
Neutral
medium confidence
Mentioned
$SI
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SINeutralLow
01

Why it matters

The newest information is the disclosed open-market sale by the COO (20,000 shares; weighted avg ~$18.7127; total ~$374K) executed over 2026-06-12 to 2026-06-15 under a 10b5-1 plan.

02

Market read

This is a routine insider sale disclosure; it can slightly influence sentiment but is unlikely to drive a major repricing absent other catalysts.

03

What to watch

Traders may over-weight insider sales; the key is whether there are concurrent disclosures (e.g., earnings, guidance, financing) which are not present here.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-16; sale executed 2026-06-12 to 2026-06-15.

Background

The article is an SEC Form 4 insider transaction disclosure for Shoulder Innovations, Inc. (SI).

Company-level read

Ticker impact

$SINeutralMedium confidence
Context

Shoulder Innovations COO Matthew Fraser sold 20,000 shares in open-market transactions under a pre-arranged 10b5-1 plan, worth ~$374K.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than a fundamental repricing.

Evidence & confidence

The filing is a routine insider sale with stated 10b5-1 pre-arrangement, reducing interpretive signal versus discretionary selling.

Market effects

No sector-level implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • Shoulder Innovations, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Ahearn Matthew Fraser

    Chief Operating Officer who sold shares in open-market transactions.

  • 10b5-1 plan

    Pre-arranged plan cited as Yes, which can reduce interpretive signal.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SIMedAI 8/10

Shoulder Innovations (SI) Q3 2026 Earnings Call Transcript

Shoulder Innovations reported Q3 2026 net revenue of $16.2M, up 38% YoY, with gross margin at 78.5%. The company raised full-year revenue guidance to $68M-$70M, up 44%-48% YoY. They launched new products, including the InSet Go glenoid implant, and saw strong surgeon adoption and procedural growth. The company expects continued momentum and plans to expand its commercial team.

$SIHigh

Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook

SHOULDER INNOVATIONS, INC. (SI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook 52% Year-to-Date 2026 Revenue Growth Grand Rapids, MI – November 5, 2026 – Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage

$SIMed

22 Humeral Head and Initiates Full Commercial Launch – Ortho Spine News

Shoulder Innovations (NYSE: SI) received FDA 510(k) clearance for its N-22 Humeral Head, a titanium implant for metal-sensitive patients. The company also launched the product commercially. The N-22 Humeral Head complements the N-22 Glenosphere, cleared earlier this year, for use in shoulder arthroplasty procedures. According to the company, this expansion may enhance surgeon relationships and operational centers. Shoulder Innovations focuses on shoulder surgical care, offering advanced implant

$SIMed

Shoulder Innovations Q2 Earnings Call Highlights

Shoulder Innovations (NYSE:SI) reported Q2 gross margin of 78.3% versus 76.2% a year earlier, with SG&A rising to $20.1M and R&D to $3.4M. Net loss narrowed to $10.2M. Cash totaled $99M at June 30. The company expects similar gross margins in 2H 2026 and plans FDA submissions for its robotic platform in 2027.